It dose-dependently decreases phosphorylation levels of Akt at S473 and T308, mTOR at S2448 and S2481 in CML cells (Fig. 3a). This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.